How New Approach Methodologies are slashing drug development costs while improving success rates
| Test Type | Traditional | NAMs | Savings | Time Saved |
|---|---|---|---|---|
| Hepatotoxicity Screening | $250,000 | $15,000 | 94% | 3-6 months |
| Cardiotoxicity Assessment | $180,000 | $25,000 | 86% | 2-4 months |
| ADMET Profiling | $500,000 | $50,000 | 90% | 6-12 months |
| Compound Screening (10,000) | $2,000,000 | $100,000 | 95% | 12-24 months |
| Efficacy Testing | $400,000 | $80,000 | 80% | 4-8 months |
| Drug-Drug Interaction | $150,000 | $20,000 | 87% | 1-2 months |
Companies adopting NAMs see significant returns through reduced failures, faster timelines, and lower testing costs
Explore how NAMs are transforming the economics of drug development
Market Analysis Success Stories NAMs Companies© 2025 Patient Analog. All rights reserved.
Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.
Free to share for educational purposes with attribution.